Tam Dang‐Tan

1.2k total citations
27 papers, 880 citations indexed

About

Tam Dang‐Tan is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tam Dang‐Tan has authored 27 papers receiving a total of 880 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tam Dang‐Tan's work include Diabetes Treatment and Management (16 papers), Diabetes Management and Research (11 papers) and Metabolism, Diabetes, and Cancer (8 papers). Tam Dang‐Tan is often cited by papers focused on Diabetes Treatment and Management (16 papers), Diabetes Management and Research (11 papers) and Metabolism, Diabetes, and Cancer (8 papers). Tam Dang‐Tan collaborates with scholars based in United States, Canada and Denmark. Tam Dang‐Tan's co-authors include Eduardo L. Franco, Jean Bourbeau, Diane Nault, Mark Greenberg, Ronald D. Barr, Helen Trottier, Leslie S. Mery, Howard Morrison, Sarah Ali and Brian Bekker Hansen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer and Diabetes.

In The Last Decade

Tam Dang‐Tan

27 papers receiving 857 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tam Dang‐Tan United States 13 275 260 252 218 138 27 880
Anna Francis Australia 16 109 0.4× 127 0.5× 62 0.2× 142 0.7× 77 0.6× 50 1.1k
Henry Kilham Australia 18 243 0.9× 311 1.2× 45 0.2× 168 0.8× 69 0.5× 49 916
Chris Dudley United Kingdom 16 299 1.1× 61 0.2× 57 0.2× 373 1.7× 128 0.9× 29 1.3k
Amanda Young United States 15 89 0.3× 84 0.3× 204 0.8× 122 0.6× 16 0.1× 71 919
Michele Donithan United States 15 181 0.7× 108 0.4× 226 0.9× 56 0.3× 49 0.4× 21 899
Susan Gilmour Canada 17 105 0.4× 221 0.8× 79 0.3× 81 0.4× 35 0.3× 48 1.1k
Bénédicte Sautenet France 18 181 0.7× 85 0.3× 35 0.1× 123 0.6× 41 0.3× 74 860
Claire Schwartz United Kingdom 14 51 0.2× 218 0.8× 39 0.2× 270 1.2× 36 0.3× 27 872
Kimberly Bischoff United States 14 41 0.1× 530 2.0× 115 0.5× 307 1.4× 74 0.5× 15 1.6k
Hugo Xi United States 7 300 1.1× 120 0.5× 238 0.9× 37 0.2× 29 0.2× 10 930

Countries citing papers authored by Tam Dang‐Tan

Since Specialization
Citations

This map shows the geographic impact of Tam Dang‐Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tam Dang‐Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tam Dang‐Tan more than expected).

Fields of papers citing papers by Tam Dang‐Tan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tam Dang‐Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tam Dang‐Tan. The network helps show where Tam Dang‐Tan may publish in the future.

Co-authorship network of co-authors of Tam Dang‐Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Tam Dang‐Tan. A scholar is included among the top collaborators of Tam Dang‐Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tam Dang‐Tan. Tam Dang‐Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Visaria, Jay, et al.. (2021). Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population. Clinical Therapeutics. 43(5). 808–821. 18 indexed citations
2.
Risebrough, Nancy, Timothy Baker, Lirong Zhang, et al.. (2021). Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics. Clinical Therapeutics. 43(11). 1812–1826.e7. 8 indexed citations
3.
Ali, Sarah, et al.. (2020). Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Journal of Medical Economics. 23(6). 650–658. 30 indexed citations
4.
Fridman, Moshe, et al.. (2020). Impact of Weight Change in Adults with Type 2 Diabetes Mellitus: A Literature Review and Critical Analysis. SHILAP Revista de lepidopterología. 2 indexed citations
5.
Ali, Sarah, Tam Dang‐Tan, William J. Valentine, & Brian Bekker Hansen. (2020). Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States. Advances in Therapy. 37(2). 869–882. 37 indexed citations
6.
Fridman, Moshe, et al.. (2020). <p>Impact of Weight Change in Adults with Type 2 Diabetes Mellitus: A Literature Review and Critical Analysis</p>. ClinicoEconomics and Outcomes Research. Volume 12. 555–566. 7 indexed citations
7.
Johansen, Pierre, Barnaby Hunt, Neeraj N. Iyer, Tam Dang‐Tan, & Richard F. Pollock. (2019). A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. Advances in Therapy. 36(5). 1190–1199. 8 indexed citations
8.
Hunt, Barnaby, Brian Bekker Hansen, Åsa Ericsson, et al.. (2019). Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Advances in Therapy. 36(12). 3483–3493. 18 indexed citations
9.
10.
Wilkinson, Lars, Barnaby Hunt, Pierre Johansen, et al.. (2018). Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. Diabetes Therapy. 9(3). 951–961. 16 indexed citations
11.
12.
Shah, Dhvani, et al.. (2018). Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective. ClinicoEconomics and Outcomes Research. Volume 10. 791–803. 16 indexed citations
13.
14.
Hunt, Barnaby, et al.. (2017). Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States. Journal of Medical Economics. 20(11). 1117–1120. 8 indexed citations
15.
Dang‐Tan, Tam, Shiyuan Zhang, Afisi Ismaila, et al.. (2017). The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, Canada. Canadian Respiratory Journal. 2017. 1–10. 5 indexed citations
16.
Dang‐Tan, Tam, Helen Trottier, Leslie S. Mery, et al.. (2009). Determinants of delays in treatment initiation in children and adolescents diagnosed with leukemia or lymphoma in Canada. International Journal of Cancer. 126(8). 1936–1943. 33 indexed citations
17.
Dang‐Tan, Tam, Helen Trottier, Leslie S. Mery, et al.. (2008). Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatric Blood & Cancer. 51(4). 468–474. 90 indexed citations
18.
Dang‐Tan, Tam & Eduardo L. Franco. (2007). Diagnosis delays in childhood cancer. Cancer. 110(4). 703–713. 202 indexed citations
19.
Dang‐Tan, Tam, Salaheddin M. Mahmud, Riccardo Puntoni, & Eduardo L. Franco. (2004). Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene. 23(38). 6535–6540. 27 indexed citations
20.
Bourbeau, Jean, Diane Nault, & Tam Dang‐Tan. (2003). Self-management and behaviour modification in COPD. Patient Education and Counseling. 52(3). 271–277. 257 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Francis Breakdown of academic impact, for papers by Henry Kilham Breakdown of academic impact, for papers by Chris Dudley Breakdown of academic impact, for papers by Amanda Young Breakdown of academic impact, for papers by Michele Donithan Breakdown of academic impact, for papers by Susan Gilmour Breakdown of academic impact, for papers by Bénédicte Sautenet Breakdown of academic impact, for papers by Claire Schwartz Breakdown of academic impact, for papers by Kimberly Bischoff Breakdown of academic impact, for papers by Hugo Xi
Rankless by CCL
2026